Boston Scientific generated $2.7 billion in sales during its fiscal third quarter, which ended Sept. 30. "We have a robust cadence of new product launches across our portfolio, and in the third quarter, we delivered strong sequential improvement in our financial performance," said company CEO and chairman Mike Mahoney.
Boston Scientific reports $2.7B in Q3 sales
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.